| Issue Date | Title | Author(s) |
| 2020 | Antiplatelet activity of new derivatives of benzimidazole containing sterically hindered phenolic group in their structure | Spasov, A. A.; Kucheryavenko, A. F.; Gaidukova, K. A.; Kosolapov, V. A.; Zhukovskaya, O. N. |
| 2025 | Anxiolytic, antidepressant and analgesic activities of novel derivatives of 1-(3-phenylpyrrol-2-yl)-1,3-dihydro-2H-benzimidazol-2-one | Maltseva, M. O.; Adzhienko, K. I.; Musaev, R. I.; Spasov, A. A.; Mamedov, V. A. |
| 2023 | Aversion-related effects of kappa-opioid agonist U-50488 on neural activity and functional connectivity between amygdala, ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens | Kalitin, K. V.; Spasov, A. A.; Mukha, O. Y. |
| 2021 | Distribution, excretion and metabolic pathways of a single parenteral administration of kappa-opioid receptor agonist RU-1205 | Spasov, A. A.; Smirnova, L. A.; Grechko, O. I.; Eliseeva, N. V.; Lifanova, Yu. V. |
| 2021 | Effect of adjuvant drugs on the analgesic activity of opioid morphine analgesics and compound RU-1205 | Spasov, A. A.; Grechko, O. I.; Eliseeva, N. V.; Lifanova, Yu. V.; Aleksandrenkova, A. N. |
| 2024 | Effects of kappa-opioid agonist U-50488 and p38 MAPK inhibitor SB203580 on the spike activity of pyramidal neurons in the basolateral amygdala | Kalitin, K. V.; Spasov, A. A.; Mukha, O. Y. |
| 2020 | Influence of Diazepino [1,2-a] benzimidazole derivative (DAB-19) on behavioral aspects of animals | Maltsev, D. V.; Spasov, A. A.; Miroshnikov, M. V.; Skripka, M. O.; Divaeva, L. N. |
| 2021 | Screening of anxiolytic properties and analysis of structure-activity relationship of new derivatives of 6-(4-methoxy)-7H-[1,2,4] triazolo [3,4-a] [2,3] benzodiazepine under the code RD | Skripka, M. O.; Spasov, A. A.; Maltsev, D. V.; Miroshnikov, M. V.; Yakovlev, D. S. |
| 2022 | Search for compounds with antioxidant and antiradical activity among N9-substituted 2-(biphenyl-4-yl)imidazo[1,2-a]benzimidazoles | Spasov, A. A.; Brigadirova, A. A.; Zhukovskaya, O. N. |
| 2020 | Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205 | Spasov, A. A.; Zvartau, E. E.; Grechko, O. I.; Eliseeva, N. V.; Semenova, Yu. V. |
| 2025 | The prefrontal cortex as a target for the atypical antipsychotic RU-31 with 5-HT2A antagonistic activity in the treatment of cognitive symptoms | Kalitin, K. V.; Mukha, O. Y.; Voynov, V. B.; Spasov, A. A. |
